Natco Pharma
Ticker > Company >

Natco Pharma share price

Natco Pharma Ltd.

NSE: NATCOPHARM BSE: 524816 SECTOR: Pharmaceuticals & Drugs  125k   488   92

1376.40
+10.25 (0.75%)
BSE: Today, 03:54 PM

Price Summary

Today's High

₹ 1389.35

Today's Low

₹ 1366.15

52 Week High

₹ 1638.35

52 Week Low

₹ 752.55

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 24652.68 Cr.

Enterprise Value

₹ 24150.98 Cr.

No. of Shares

17.91 Cr.

P/E

13.41

P/B

3.6

Face Value

₹ 2

Div. Yield

0.69 %

Book Value (TTM)

₹  382.03

CASH

₹ 864.9 Cr.

DEBT

₹ 363.2 Cr.

Promoter Holding

49.62 %

EPS (TTM)

₹  102.65

Sales Growth

51.8%

ROE

25.38 %

ROCE

29.02%

Profit Growth

105.09 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Natco Pharma Ltd.

Molnunat

Index Presence

The company is present in 23 Indices.

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
41072.05
  -76.8499999999985 (-0.186760763957239%)

NIFTY500

Nifty 500
21820.85
  -183.5 (-0.833926019173481%)

NIFTYPHARMA

Nifty Pharma
21740.1
  -28.75 (-0.13206944785783%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
18989.75
  -86.25 (-0.452138813168379%)

NIFTYSMALL

NIFTY Smallcap 100
17596.6
  -80.75 (-0.456799237442262%)

NIFTYSMALLCAP250

Nifty Smallcap 250
16747.85
  -97.4000000000015 (-0.578204538371363%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
15270.4
  -112.75 (-0.732944812993441%)

NY500MUL50:30:20

Nifty500 Multicap India Manufacturing 50:30:20
14330.7
  -89.2999999999993 (-0.619278779472954%)

NIFTYTOTALMCAP

NIFTY Total Market
12302.6
  -103.449999999999 (-0.833867346979889%)

NIFTYSMALLCAP50

Nifty Smallcap 50
8513.5
  -22.6000000000004 (-0.264757910521207%)

NFT500EQUAL

Nifty 500 Equal Weight
13723.64
  100.23 (0.735718883891767%)

NFTSML250MOMQ100

Nifty Smallcap250 Momentum Quality 100 index
48087.05
  523 (1.0995699483118%)

NIFTYFULLMIDCAP100

NIFTY FULL MIDCAP 100
5987.56
  -42.7999999999993 (-0.709742038617911%)

NYMIDSML400MQ100

Nifty MidSmallcap400 Momentum Quality 100 Index
49544.2
  461.649999999994 (0.940558304326067%)

SHARIAH500

Nifty500 Shariah
7292.96
  47.2600000000002 (0.652248920049137%)

SMLCAP

Bse SmallCap
52141.15
  -349.790000000001 (-0.666381665102589%)

BSE HC

Bse Healthcare
42447.07
  46.9599999999991 (0.11075442964652%)

BSE500

Bse 500
34361.41
  -289.419999999998 (-0.835246947908597%)

MSL400

Bse 400 MidSmallCap Index
11623.42
  -57.1299999999992 (-0.489103680905434%)

SMLSEL

Bse SmallCap Select Index
7765.07
  -13.8900000000003 (-0.178558573382559%)

SML250

Bse 250 SmallCap Index
6734.99
  -48.5100000000002 (-0.715117564679002%)

ALLCAP

Bse Allcap
10471.31
  71.0699999999997 (0.683349615008888%)

S&P MIDSMLCAP

Bse MidSmallCap
12963.76
  118.380000000001 (0.921576473409114%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year51.8%
3 Year29.23%
5 Year12.43%

Profit Growth

1 Year105.09%
3 Year61.62%
5 Year14.39%

ROE%

1 Year25.38%
3 Year14.36%
5 Year12.75%

ROCE %

1 Year29.02%
3 Year16.44%
5 Year14.73%

Debt/Equity

0.0649

Price to Cash Flow

20.61

Interest Cover Ratio

108.2621

CFO/PAT (5 Yr. Avg.)

0.922457095018836

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 49.62 0.00
Jun 2024 49.71 0.00
Mar 2024 49.71 0.00
Dec 2023 49.71 0.00
Sep 2023 49.71 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 61.6195897998219% for the Past 3 years.
  • The company has shown a good revenue growth of 29.2336507277335% for the Past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 108.2621.
  • The Company has been maintaining an effective average operating margins of 28.919715206723% in the last 5 years.
  • Company’s PEG ratio is 0.122911829014406.
  • The company has an efficient Cash Conversion Cycle of 22.7736 days.
  • Company has a healthy liquidity position with current ratio of 3.8509.

 Limitations

 Looks like the company does not have any serious limitations.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 930.5 625.3 964.8 1236.9 1292.6
Total Expenditure 488.2 387 512.1 473.9 501.9
Operating Profit 442.3 238.3 452.7 763 790.7
Other Income 24.7 29.5 35.9 39.8 51.4
Interest 3 3.8 4.5 4.4 3
Depreciation 40 40.4 51.6 40.4 42.2
Exceptional Items 0 0 0 0 0
Profit Before Tax 424 223.6 432.5 758 796.9
Tax 63.8 31.6 83.4 121.7 135.8
Profit After Tax 360.2 192 349.1 636.3 661.1
Adjusted EPS (Rs) 20.12 10.73 19.5 35.55 36.93

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 1790.2 1653.5 1767.8 2351 3568.9
Total Expenditure 1212.2 1238.3 1554.8 1530.2 1931.9
Operating Profit 578 415.2 213 820.8 1637
Other Income 123.8 103.5 94.6 109.4 104.7
Interest 20.6 11.3 13.3 8.6 14.5
Depreciation 98.1 115.2 138.4 150.9 171.9
Exceptional Items 0 0 0 0 0
Profit Before Tax 583.1 392.2 155.9 770.7 1555.3
Tax 108.6 82.7 16.8 133.6 248.7
Net Profit 474.5 309.5 139.1 637.1 1306.6
Adjusted EPS (Rs.) 26.07 16.96 7.62 34.91 72.99

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 36.4 36.5 36.5 36.5 35.8
Total Reserves 3833.1 4054.6 4155.4 4665.5 5556.5
Borrowings 0 0 0 0 0
Other N/C liabilities 117.5 142.9 134.9 116.9 69
Current liabilities 659.7 518.5 651.2 569 885.6
Total Liabilities 4646.7 4752.5 4978 5387.9 6546.9
Assets
Net Block 1574.5 2005.9 2174.2 2233.8 2286.7
Capital WIP 517.8 223.4 128.7 62.8 133.9
Intangible WIP 0 0 0 0 0
Investments 186.1 294.9 430.4 517.6 577.8
Loans & Advances 124.3 55.6 72.4 78.8 111.5
Other N/C Assets 4.1 4.2 4.6 0.2 26.6
Current Assets 2239.9 2168.5 2167.7 2494.7 3410.4
Total Assets 4646.7 4752.5 4978 5387.9 6546.9
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 583.1 392.2 155.9 770.7 1555.3
Adjustment 45.2 58.4 118.5 85.4 150.9
Changes in Assets & Liabilities -100.7 -190.2 -184.2 76.7 -257.8
Tax Paid -105.1 -76.9 -32.5 -148.4 -252
Operating Cash Flow 422.5 183.5 57.7 784.4 1196.4
Investing Cash Flow -165 -3.2 -92.5 -436.6 -960.5
Financing Cash Flow -261.1 -183.1 35.6 -346.8 -237.3
Net Cash Flow -3.6 -2.8 0.8 1 -1.4

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 49.71 49.71 49.71 49.71 49.62
devendranth alapati 0.01 0.01 0.01 0.01 0.01
durga devi nannapaneni 1.98 1.98 1.98 1.98 1.98
kantamani ratna kumar 0.06 0.06 0.06 0.06 0.03
natco aqua limited 0.01 0.01 0.01 0.01 0.01
natsoft information syste... 8.81 8.81 8.81 8.81 8.81
ndl infratech private lim... 0.05 0.05 0.05 0.05 0.05
neelima sita nannapaneni 0.10 0.10 0.10 0.10 0.10
rajeev nannapaneni 0.63 0.63 0.63 0.63 0.63
ramakrishna rao nannapane... 0.42 0.42 0.42 0.42 0.42
t ananda babu - - - 0.23 0.23
t anila 0.33 0.33 0.33 0.33 0.32
time cap pharma labs pri... 9.59 9.59 9.59 9.59 9.59
tummala jansi 0.04 0.04 0.04 0.04 0.04
v c nannapaneni 15.66 15.66 15.66 15.66 15.66
venkata satya swathi kant... 8.92 8.92 8.92 8.92 8.92
vidyadhari tummala 0.25 0.25 0.25 0.25 0.21
vistra itcl india limited... 2.28 2.28 2.28 2.28 2.28
vistra itcl india limited... 0.33 0.33 0.33 0.33 0.33
t anand babu 0.23 0.23 0.23 - -
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 50.29 50.29 50.29 50.29 50.38
akash bhanshali 1.01 1.01 1.01 1.01 1.01
belgrave investment fund - - 1.92 1.92 1.92
investor education and pr... - - 0.47 0.48 0.47
life insurance corporatio... - - 3.86 - 3.04
tata nifty 500 multicap i... - - - - 1.22
life insurance corporatio... 4.11 4.11 - 3.69 -
tata nifty midsmall healt... - - - 1.19 -
mirae asset large & midca... - - 2.19 - -
belgrave investment fund.... - 1.88 - - -
investor education and pr... 0.47 0.47 - - -
mirae asset midcap fund16... - 2.66 - - -
tata mutual fund- tata eq... - 1.00 - - -
icici prudential multicap... 1.73 - - - -
mirae asset healthcare fu... 2.73 - - - -
nomura singapore limited ... 1.55 - - - -
quant mutual fund - quant... 1.05 - - - -
tata mutual fund - tata s... 1.00 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Natco Pharma - Quaterly Results 12 Nov, 2:30 PM Natco Pharma - Quaterly Results 12 Nov, 2:30 PM Natco Pharma - Quaterly Results 12 Nov, 2:30 PM NATCO Pharma informs about board meeting 28 Oct, 5:32 PM NATCO Pharma informs about regulatory update 7 Oct, 9:51 AM Natco Pharma’s arm makes $8 million investment in eGenesis 4 Sep, 12:56 PM Natco Pharma informs about disclosure 28 Aug, 1:19 PM Natco Pharma informs about earnings call transcript 21 Aug, 4:58 PM Natco Pharma - Quaterly Results 12 Aug, 2:00 PM Natco Pharma - Quaterly Results 12 Aug, 2:00 PM Natco Pharma - Quaterly Results 12 Aug, 2:00 PM Natco Pharma informs about loss of share certificate 3 Aug, 3:52 PM NATCO Pharma informs about demise of independent director 31 Jul, 12:03 PM NATCO Pharma informs about issuance of duplicate share certificates 29 Jul, 5:16 PM Natco Pharma informs about change in management 27 Jul, 4:02 PM Natco Pharma informs about press release 28 May, 5:10 PM Natco Pharma - Quaterly Results 27 May, 4:42 PM Natco Pharma - Quaterly Results 27 May, 4:42 PM Natco Pharma - Quaterly Results 27 May, 4:42 PM NATCO Pharma informs about earnings call 15 May, 5:19 PM Natco Pharma informs about details of loss of certificate 14 May, 5:33 PM NATCO Pharma informs about disclosure 23 Apr, 4:50 PM NATCO Pharma informs about press release 18 Apr, 10:21 AM Natco Pharma gets warning letter from USFDA for Telangana plant 9 Apr, 5:16 PM NATCO Pharma informs about updates 9 Apr, 10:34 AM NATCO Pharma informs about certificate 6 Apr, 11:16 AM Natco Pharma informs about details of loss of certificate 5 Apr, 11:19 AM Natco Pharma informs about analyst meet 2 Mar, 3:17 PM NATCO Pharma informs about analyst meet 2 Mar, 12:52 PM Natco Pharma informs about details of loss of certificate 1 Mar, 4:49 PM Natco Pharma informs about press release 26 Feb, 5:12 PM Natco Pharma informs about disclosure 23 Feb, 2:31 PM Natco Pharma informs about notice postal ballot 22 Feb, 3:11 PM Natco Pharma - Quaterly Results 14 Feb, 2:08 PM Natco Pharma - Quaterly Results 14 Feb, 2:08 PM Natco Pharma - Quaterly Results 14 Feb, 2:08 PM Natco Pharma invests around $2 million in Cellogen Therapeutics 17 Jan, 5:35 PM Natco Pharma submits analyst meet intimation 25 Nov, 11:51 AM Natco Pharma informs about analyst meet 16 Nov, 1:04 PM Natco Pharma - Quaterly Results 14 Nov, 2:14 PM Natco Pharma - Quaterly Results 14 Nov, 2:14 PM Natco Pharma - Quaterly Results 14 Nov, 2:14 PM Natco Pharma submits analyst meet intimation 9 Nov, 4:47 PM Natco Pharma informs about book closure 21 Sep, 1:01 PM NATCO Pharma informs about disclosure 8 Sep, 10:22 AM NATCO Pharma informs about issuance of duplicate share certificate 7 Sep, 2:37 PM Natco Pharma informs about newspaper publication 6 Sep, 4:26 PM Natco Pharma makes strategic investment in ISCA Inc 31 Aug, 10:23 AM NATCO Pharma informs about issuance of duplicate share certificate 25 Aug, 5:16 PM Natco Pharma - Quaterly Results 9 Aug, 2:50 PM

Natco Pharma Stock Price Analysis and Quick Research Report. Is Natco Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Natco Pharma and its performance over the period of time. Natco Pharma stock price today is Rs 1375.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Natco Pharma cash from the operating activity was Rs 1196.4 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Natco Pharma has a Debt to Equity ratio of 0.0649 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Natco Pharma , the EPS growth was 109.0955 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Natco Pharma has OPM of 45.8684748802152 % which is a good sign for profitability.
     
  • ROE: Natco Pharma have a healthy ROE of 25.3849 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Natco Pharma is Rs 1375. One can use valuation calculators of ticker to know if Natco Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Natco Pharma

Natco Pharma Ltd Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis 

 

Welcome to the stock analysis page of Natco Pharma Ltd., where we provide a technical and comprehensive evaluation of the company's financial performance and growth potential. Our analysis is tailored for long-term stock investors, including doctors, who seek an in-depth understanding of the company's financial health. Our website offers pre-built screening tools, allowing investors to analyze specific parameters with ease. Annual reports and quarterly results are available as downloadable files on our website.

Natco Pharma Ltd Share Price

Track the share price trends of Natco Pharma Ltd. using our intuitive charts and real-time updates. Ticker platform provides historical data and analysis of the company's stock performance, enabling investors to make informed investment decisions.

Natco Pharma Ltd Balance Sheet

Evaluate the financial position of Natco Pharma Ltd. with our comprehensive balance sheet analysis. Utilize our premium features, including DCF Analysis, BVPS Analysis, Earnings Multiple approach, and DuPont Analysis, to calculate the company's fair value and growth potential accurately.

Natco Pharma Ltd Annual Report

Obtain the annual reports of Natco Pharma Ltd. from our website. These reports offer insights into the company's operational and financial performance, as well as strategic initiatives for the year. Ticker pre-built screening tools facilitate the filtering of reports based on specific parameters.

Natco Pharma Ltd Dividend

Stay updated on Natco Pharma Ltd.'s dividend payouts and dividend history with our user-friendly interface. Our website provides easy access to dividend-related information, allowing investors to review the company's past dividend payouts and consider them when making investment decisions.

Natco Pharma Ltd Quarterly Result

Access the quarterly results of Natco Pharma Ltd. through downloadable files available on our website. Ticker platform offers a comprehensive analysis of the company's financial performance, and our premium features, including DCF Analysis, Earnings Multiple Approach, and DuPont Analysis, enhance the evaluation of the company's growth prospects.

Natco Pharma Ltd Stock Price

Keep track of Natco Pharma Ltd.'s stock price movements utilizing our user-friendly charts and real-time updates. Our platform offers in-depth analysis of the company's historical price trends, enabling investors to make informed investment decisions.

Natco Pharma Ltd Price Chart

Visualize the stock price movements of Natco Pharma Ltd. through our detailed price charts. Ticker platform provides insights into the company's historical performance, and our premium features, including fair value calculation using DCF Analysis, Earnings Multiple, and DuPont Analysis, offer investors greater clarity on the company's financial health.

Natco Pharma Ltd News

Stay updated with the latest news and developments of Natco Pharma Ltd. with our comprehensive news aggregation platform. Our reliable sources gather the most relevant news, enabling investors to make informed investment decisions.

Natco Pharma Ltd Concall Transcripts

Access the conference call transcripts of Natco Pharma Ltd. through downloadable files available on our website. These transcripts provide valuable insights into the company's management discussions, milestones, and financial performance. Utilize our premium features, including DCF Analysis, Earnings Multiple Approach, and DuPont Analysis, to enhance the evaluation of the company's financial health.

Natco Pharma Ltd Investor Presentations

Explore the investor presentations of Natco Pharma Ltd. These presentations provide detailed overviews of the company's business operations, growth strategies, and financial performance. Our platform offers features to filter the presentations based on specific parameters, allowing users to identify relevant information for their investment decisions.

Natco Pharma Ltd Promoters

Get acquainted with the promoters of Natco Pharma Ltd., the individuals responsible for the company's growth and success. Ticker platform provides detailed information about the promoters, their backgrounds, and their contributions to the company's development.

Natco Pharma Ltd Shareholders

Understand the shareholders of Natco Pharma Ltd., including institutional investors and retail shareholders. The shareholder structure can provide valuable insights into the company's ownership patterns and potential market influence.

Natco Pharma Ltd ROCE

Return on Capital Employed (ROCE) is a key metric used to evaluate Natco Pharma Ltd's efficiency in generating returns from its capital investments. ROCE indicates how well the company utilizes its capital to generate profits for its shareholders. Investors can access the ROCE data for Natco Pharma Ltd conveniently located in the financials table or the ratio section provided on this page.

Natco Pharma Ltd EBITDA

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is a crucial measure of Natco Pharma Ltd's operational performance and profitability, excluding non-operating expenses. Analyzing EBITDA provides insights into the company's core operational earnings. The EBITDA data for Natco Pharma Ltd is readily accessible in the financials table or the ratio section on this page.

Natco Pharma Ltd DPS

Dividends Per Share (DPS) represents the portion of Natco Pharma Ltd's profits distributed to shareholders per outstanding share. DPS is an important metric for investors seeking regular dividend income. Investors can refer to the financials table or the ratio section provided on this page for Natco Pharma Ltd's DPS data.

Natco Pharma Ltd EPS

Earnings Per Share (EPS) offers insights into the portion of Natco Pharma Ltd's profit allocated to each outstanding share of its common stock. Analyzing EPS helps investors understand the company's profitability on a per-share basis. The EPS data for Natco Pharma Ltd can be viewed in the financials table or the dedicated ratio section above.

Read More
X